Cash Flow Statement

Amortization Amortization Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Depreciation & Amortization (IS)EBIAT Leases Loans and Notes Receivables Long-Term Debt Issuances Long-Term Debt Repayments Non-Current Receivables Other Gross PP&E Adjustments Other Gross PP&E Adjustments Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased Short-Term Debt issuances

Ratios

Quantum Biopharma (QNTM) Long-Term Debt Issuances (2024 - 2025)

Quantum Biopharma's Long-Term Debt Issuances history spans 2 years, with the latest figure at -$31372.0 for Q4 2025.

On a quarterly basis, Long-Term Debt Issuances rose 98.13% to -$31372.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 million, a 583.64% increase, with the full-year FY2025 number at $2.1 million, up 583.64% from a year prior.
Long-Term Debt Issuances hit -$31372.0 in Q4 2025 for Quantum Biopharma, down from $34308.0 in the prior quarter.
Over the last five years, Long-Term Debt Issuances for QNTM hit a ceiling of $2.7 million in Q1 2025 and a floor of -$1.7 million in Q4 2024.